Different classes of antibiotics given to women routinely for preventing infection at caesarean section

Gillian M I Gyte, Lixia Dou, Juan C Vazquez, Gillian M I Gyte, Lixia Dou, Juan C Vazquez

Abstract

Background: Caesarean section increases the risk of postpartum infection for women and prophylactic antibiotics have been shown to reduce the incidence; however, there are adverse effects. It is important to identify the most effective class of antibiotics to use and those with the least adverse effects.

Objectives: To determine, from the best available evidence, the balance of benefits and harms between different classes of antibiotic given prophylactically to women undergoing caesarean section.

Search methods: We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (30 September 2014) and reference lists of retrieved papers.

Selection criteria: We included randomised controlled trials comparing different classes of prophylactic antibiotics given to women undergoing caesarean section. We excluded trials that compared drugs with placebo or drugs within a specific class; these are assessed in other Cochrane reviews.

Data collection and analysis: Two review authors independently assessed the studies for inclusion, assessed risk of bias and carried out data extraction.

Main results: We included 35 studies of which 31 provided data on 7697 women. For the main comparison between cephalosporins versus penicillins, there were 30 studies of which 27 provided data on 7299 women. There was a lack of good quality data and important outcomes often included only small numbers of women.For the comparison of a single cephalosporin versus a single penicillin (Comparison 1 subgroup 1), we found no significant difference between these classes of antibiotics for our chosen most important seven outcomes namely: maternal sepsis - there were no women with sepsis in the two studies involving 346 women; maternal endometritis (risk ratio (RR) 1.11, 95% confidence interval (CI) 0.81 to 1.52, nine studies, 3130 women, random effects, moderate quality of the evidence); maternal wound infection (RR 0.83, 95% CI 0.38 to 1.81, nine studies, 1497 women, random effects, low quality of the evidence), maternal urinary tract infection (RR 1.48, 95% CI 0.89 to 2.48, seven studies, 1120 women, low quality of the evidence) and maternal composite adverse effects (RR 2.02, 95% CI 0.18 to 21.96, three studies, 1902 women, very low quality of the evidence). None of the included studies looked for infant sepsis nor infant oral thrush.This meant we could only conclude that the current evidence shows no overall difference between the different classes of antibiotics in terms of reducing maternal infections after caesarean sections. However, none of the studies reported on infections diagnosed after the initial postoperative hospital stay. We were unable to assess what impact, if any, the use of different classes of antibiotics might have on bacterial resistance.

Authors' conclusions: Based on the best currently available evidence, cephalosporins and penicillins have similar efficacy at caesarean section when considering immediate postoperative infections. We have no data for outcomes on the baby, nor on late infections (up to 30 days) in the mother. Clinicians need to consider bacterial resistance and women's individual circumstances.

Conflict of interest statement

None known.

Figures

1
1
Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
2
2
Funnel plot of comparison: 1 Cephalosporins versus penicillins ‐ all women, outcome: 1.2 Maternal endometritis.
3
3
Funnel plot of comparison: 1 Cephalosporins versus penicillins ‐ all women, outcome: 1.7 Maternal urinary tract infection.
4
4
Funnel plot of comparison: 1 Cephalosporins versus penicillins ‐ all women, outcome: 1.5 Maternal fever (febrile morbidity).
5
5
Funnel plot of comparison: 1 Cephalosporins versus penicillins ‐ all women, outcome: 1.6 Maternal wound infection.
1.1. Analysis
1.1. Analysis
Comparison 1 Cephalosporins versus penicillins ‐ all women, Outcome 1 Maternal sepsis.
1.2. Analysis
1.2. Analysis
Comparison 1 Cephalosporins versus penicillins ‐ all women, Outcome 2 Maternal endometritis.
1.5. Analysis
1.5. Analysis
Comparison 1 Cephalosporins versus penicillins ‐ all women, Outcome 5 Maternal fever (febrile morbidity).
1.6. Analysis
1.6. Analysis
Comparison 1 Cephalosporins versus penicillins ‐ all women, Outcome 6 Maternal wound infection.
1.7. Analysis
1.7. Analysis
Comparison 1 Cephalosporins versus penicillins ‐ all women, Outcome 7 Maternal urinary tract infection.
1.9. Analysis
1.9. Analysis
Comparison 1 Cephalosporins versus penicillins ‐ all women, Outcome 9 Maternal composite serious infectious complication.
1.10. Analysis
1.10. Analysis
Comparison 1 Cephalosporins versus penicillins ‐ all women, Outcome 10 Maternal composite adverse effects.
1.11. Analysis
1.11. Analysis
Comparison 1 Cephalosporins versus penicillins ‐ all women, Outcome 11 Maternal allergic reactions.
1.12. Analysis
1.12. Analysis
Comparison 1 Cephalosporins versus penicillins ‐ all women, Outcome 12 Maternal nausea.
1.13. Analysis
1.13. Analysis
Comparison 1 Cephalosporins versus penicillins ‐ all women, Outcome 13 Maternal vomiting.
1.14. Analysis
1.14. Analysis
Comparison 1 Cephalosporins versus penicillins ‐ all women, Outcome 14 Maternal diarrhoea.
1.15. Analysis
1.15. Analysis
Comparison 1 Cephalosporins versus penicillins ‐ all women, Outcome 15 Maternal skin rash.
1.21. Analysis
1.21. Analysis
Comparison 1 Cephalosporins versus penicillins ‐ all women, Outcome 21 Maternal length of hospital stay.
2.1. Analysis
2.1. Analysis
Comparison 2 Cephalosporins versus penicillins ‐ by type of caesarean, Outcome 1 Maternal sepsis.
2.2. Analysis
2.2. Analysis
Comparison 2 Cephalosporins versus penicillins ‐ by type of caesarean, Outcome 2 Maternal endometritis.
3.1. Analysis
3.1. Analysis
Comparison 3 Cephalosporins versus penicillins ‐ by timing of administration, Outcome 1 Maternal sepsis.
3.2. Analysis
3.2. Analysis
Comparison 3 Cephalosporins versus penicillins ‐ by timing of administration, Outcome 2 Maternal endometritis.
4.1. Analysis
4.1. Analysis
Comparison 4 Cephalosporins versus penicillins ‐ by route of administration, Outcome 1 Maternal sepsis.
4.2. Analysis
4.2. Analysis
Comparison 4 Cephalosporins versus penicillins ‐ by route of administration, Outcome 2 Maternal endometritis.
5.2. Analysis
5.2. Analysis
Comparison 5 Cephalosporin (1st generation B1) versus penicillins (extended spectrum A3), Outcome 2 Maternal endometritis.
5.5. Analysis
5.5. Analysis
Comparison 5 Cephalosporin (1st generation B1) versus penicillins (extended spectrum A3), Outcome 5 Maternal fever (febrile morbidity).
5.6. Analysis
5.6. Analysis
Comparison 5 Cephalosporin (1st generation B1) versus penicillins (extended spectrum A3), Outcome 6 Maternal wound infection.
5.10. Analysis
5.10. Analysis
Comparison 5 Cephalosporin (1st generation B1) versus penicillins (extended spectrum A3), Outcome 10 Maternal composite adverse effects.
6.2. Analysis
6.2. Analysis
Comparison 6  Cephalosporin (1st generation B1) versus penicillins  (ampicillin A4), Outcome 2 Maternal endometritis.
6.5. Analysis
6.5. Analysis
Comparison 6  Cephalosporin (1st generation B1) versus penicillins  (ampicillin A4), Outcome 5 Maternal fever (febrile morbidity).
6.6. Analysis
6.6. Analysis
Comparison 6  Cephalosporin (1st generation B1) versus penicillins  (ampicillin A4), Outcome 6 Maternal wound infection.
6.7. Analysis
6.7. Analysis
Comparison 6  Cephalosporin (1st generation B1) versus penicillins  (ampicillin A4), Outcome 7 Maternal urinary tract infection.
6.10. Analysis
6.10. Analysis
Comparison 6  Cephalosporin (1st generation B1) versus penicillins  (ampicillin A4), Outcome 10 Maternal composite adverse effects.
6.11. Analysis
6.11. Analysis
Comparison 6  Cephalosporin (1st generation B1) versus penicillins  (ampicillin A4), Outcome 11 Maternal allergic reactions.
6.15. Analysis
6.15. Analysis
Comparison 6  Cephalosporin (1st generation B1) versus penicillins  (ampicillin A4), Outcome 15 Maternal skin rash.
6.21. Analysis
6.21. Analysis
Comparison 6  Cephalosporin (1st generation B1) versus penicillins  (ampicillin A4), Outcome 21 Maternal length of hospital stay.
7.1. Analysis
7.1. Analysis
Comparison 7 Cephalosporin (2nd generation B2) versus penicillins (extended‐spectrum A3), Outcome 1 Maternal sepsis.
7.2. Analysis
7.2. Analysis
Comparison 7 Cephalosporin (2nd generation B2) versus penicillins (extended‐spectrum A3), Outcome 2 Maternal endometritis.
7.5. Analysis
7.5. Analysis
Comparison 7 Cephalosporin (2nd generation B2) versus penicillins (extended‐spectrum A3), Outcome 5 Maternal fever (febrile morbidity).
7.6. Analysis
7.6. Analysis
Comparison 7 Cephalosporin (2nd generation B2) versus penicillins (extended‐spectrum A3), Outcome 6 Maternal wound infection.
7.7. Analysis
7.7. Analysis
Comparison 7 Cephalosporin (2nd generation B2) versus penicillins (extended‐spectrum A3), Outcome 7 Maternal urinary tract infection.
7.10. Analysis
7.10. Analysis
Comparison 7 Cephalosporin (2nd generation B2) versus penicillins (extended‐spectrum A3), Outcome 10 Maternal composite adverse effects.
7.15. Analysis
7.15. Analysis
Comparison 7 Cephalosporin (2nd generation B2) versus penicillins (extended‐spectrum A3), Outcome 15 Maternal skin rash.
8.1. Analysis
8.1. Analysis
Comparison 8 Cephalosporin (2nd generation B2) versus penicillins (ampicillin A4), Outcome 1 Maternal sepsis.
8.2. Analysis
8.2. Analysis
Comparison 8 Cephalosporin (2nd generation B2) versus penicillins (ampicillin A4), Outcome 2 Maternal endometritis.
8.5. Analysis
8.5. Analysis
Comparison 8 Cephalosporin (2nd generation B2) versus penicillins (ampicillin A4), Outcome 5 Maternal fever (febrile morbidity).
8.6. Analysis
8.6. Analysis
Comparison 8 Cephalosporin (2nd generation B2) versus penicillins (ampicillin A4), Outcome 6 Maternal wound infection.
8.7. Analysis
8.7. Analysis
Comparison 8 Cephalosporin (2nd generation B2) versus penicillins (ampicillin A4), Outcome 7 Maternal urinary tract infection.
8.10. Analysis
8.10. Analysis
Comparison 8 Cephalosporin (2nd generation B2) versus penicillins (ampicillin A4), Outcome 10 Maternal composite adverse effects.
8.11. Analysis
8.11. Analysis
Comparison 8 Cephalosporin (2nd generation B2) versus penicillins (ampicillin A4), Outcome 11 Maternal allergic reactions.
8.15. Analysis
8.15. Analysis
Comparison 8 Cephalosporin (2nd generation B2) versus penicillins (ampicillin A4), Outcome 15 Maternal skin rash.
9.1. Analysis
9.1. Analysis
Comparison 9 Cephalosporin (3rd generation B3) versus penicillins (extended‐spectrum A3), Outcome 1 Maternal sepsis.
9.2. Analysis
9.2. Analysis
Comparison 9 Cephalosporin (3rd generation B3) versus penicillins (extended‐spectrum A3), Outcome 2 Maternal endometritis.
9.6. Analysis
9.6. Analysis
Comparison 9 Cephalosporin (3rd generation B3) versus penicillins (extended‐spectrum A3), Outcome 6 Maternal wound infection.
9.7. Analysis
9.7. Analysis
Comparison 9 Cephalosporin (3rd generation B3) versus penicillins (extended‐spectrum A3), Outcome 7 Maternal urinary tract infection.
9.9. Analysis
9.9. Analysis
Comparison 9 Cephalosporin (3rd generation B3) versus penicillins (extended‐spectrum A3), Outcome 9 Maternal composite serious infectious complication.
9.10. Analysis
9.10. Analysis
Comparison 9 Cephalosporin (3rd generation B3) versus penicillins (extended‐spectrum A3), Outcome 10 Maternal composite adverse effects.
9.11. Analysis
9.11. Analysis
Comparison 9 Cephalosporin (3rd generation B3) versus penicillins (extended‐spectrum A3), Outcome 11 Maternal allergic reactions.
9.12. Analysis
9.12. Analysis
Comparison 9 Cephalosporin (3rd generation B3) versus penicillins (extended‐spectrum A3), Outcome 12 Maternal nausea.
9.13. Analysis
9.13. Analysis
Comparison 9 Cephalosporin (3rd generation B3) versus penicillins (extended‐spectrum A3), Outcome 13 Maternal vomiting.
9.14. Analysis
9.14. Analysis
Comparison 9 Cephalosporin (3rd generation B3) versus penicillins (extended‐spectrum A3), Outcome 14 Maternal diarrhoea.
9.15. Analysis
9.15. Analysis
Comparison 9 Cephalosporin (3rd generation B3) versus penicillins (extended‐spectrum A3), Outcome 15 Maternal skin rash.
10.2. Analysis
10.2. Analysis
Comparison 10 Cephalosporin (3rd generation B3) versus penicillins (ampicillins A4), Outcome 2 Maternal endometritis.
10.5. Analysis
10.5. Analysis
Comparison 10 Cephalosporin (3rd generation B3) versus penicillins (ampicillins A4), Outcome 5 Maternal fever (febrile morbidity).
10.6. Analysis
10.6. Analysis
Comparison 10 Cephalosporin (3rd generation B3) versus penicillins (ampicillins A4), Outcome 6 Maternal wound infection.
10.7. Analysis
10.7. Analysis
Comparison 10 Cephalosporin (3rd generation B3) versus penicillins (ampicillins A4), Outcome 7 Maternal urinary tract infection.
10.9. Analysis
10.9. Analysis
Comparison 10 Cephalosporin (3rd generation B3) versus penicillins (ampicillins A4), Outcome 9 Maternal composite serious infectious complication.
10.10. Analysis
10.10. Analysis
Comparison 10 Cephalosporin (3rd generation B3) versus penicillins (ampicillins A4), Outcome 10 Maternal composite adverse effects.
10.11. Analysis
10.11. Analysis
Comparison 10 Cephalosporin (3rd generation B3) versus penicillins (ampicillins A4), Outcome 11 Maternal allergic reactions.
10.13. Analysis
10.13. Analysis
Comparison 10 Cephalosporin (3rd generation B3) versus penicillins (ampicillins A4), Outcome 13 Maternal vomiting.
10.15. Analysis
10.15. Analysis
Comparison 10 Cephalosporin (3rd generation B3) versus penicillins (ampicillins A4), Outcome 15 Maternal skin rash.
10.21. Analysis
10.21. Analysis
Comparison 10 Cephalosporin (3rd generation B3) versus penicillins (ampicillins A4), Outcome 21 Maternal length of hospital stay.
11.1. Analysis
11.1. Analysis
Comparison 11 Fluoroquinolones (C) vs penicillins  (A), Outcome 1 Maternal sepsis.
11.2. Analysis
11.2. Analysis
Comparison 11 Fluoroquinolones (C) vs penicillins  (A), Outcome 2 Maternal endometritis.
11.6. Analysis
11.6. Analysis
Comparison 11 Fluoroquinolones (C) vs penicillins  (A), Outcome 6 Maternal wound infection.
11.7. Analysis
11.7. Analysis
Comparison 11 Fluoroquinolones (C) vs penicillins  (A), Outcome 7 Maternal urinary tract infection.
12.1. Analysis
12.1. Analysis
Comparison 12 Fluoroquinolones (C) vs cephalosporins (B), Outcome 1 Maternal sepsis.
12.2. Analysis
12.2. Analysis
Comparison 12 Fluoroquinolones (C) vs cephalosporins (B), Outcome 2 Maternal endometritis.
12.6. Analysis
12.6. Analysis
Comparison 12 Fluoroquinolones (C) vs cephalosporins (B), Outcome 6 Maternal wound infection.
12.7. Analysis
12.7. Analysis
Comparison 12 Fluoroquinolones (C) vs cephalosporins (B), Outcome 7 Maternal urinary tract infection.
13.2. Analysis
13.2. Analysis
Comparison 13 Other antibiotic regimens (D to I) versus penicillins (A), Outcome 2 Maternal endometritis.
13.6. Analysis
13.6. Analysis
Comparison 13 Other antibiotic regimens (D to I) versus penicillins (A), Outcome 6 Maternal wound infection.
14.2. Analysis
14.2. Analysis
Comparison 14 Other antibiotic regimens (D to I) versus cephalosporins (B), Outcome 2 Maternal endometritis.
14.5. Analysis
14.5. Analysis
Comparison 14 Other antibiotic regimens (D to I) versus cephalosporins (B), Outcome 5 Maternal fever (febrile morbidity).
14.6. Analysis
14.6. Analysis
Comparison 14 Other antibiotic regimens (D to I) versus cephalosporins (B), Outcome 6 Maternal wound infection.
14.7. Analysis
14.7. Analysis
Comparison 14 Other antibiotic regimens (D to I) versus cephalosporins (B), Outcome 7 Maternal urinary tract infection.
15.2. Analysis
15.2. Analysis
Comparison 15 Other antibiotic regimens versus different antibiotic regimens, Outcome 2 Maternal endometritis.
15.6. Analysis
15.6. Analysis
Comparison 15 Other antibiotic regimens versus different antibiotic regimens, Outcome 6 Maternal wound infection.
15.7. Analysis
15.7. Analysis
Comparison 15 Other antibiotic regimens versus different antibiotic regimens, Outcome 7 Maternal urinary tract infection.
15.27. Analysis
15.27. Analysis
Comparison 15 Other antibiotic regimens versus different antibiotic regimens, Outcome 27 Stillbirth (not‐prespecified).

Source: PubMed

3
Sottoscrivi